Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

Annals of Oncology

Volumn 13, Issue 7, 2002, Pages 1036-1043

  Larsimont, D ^a   Gancberg, D ^a   Di Leo, A ^a   Cardoso, F ^a   Rouas, G ^a   Pedrocchi, M ^b   Paesmans, M ^c   Verhest, A ^a   Bernard Marty, C ^a   Piccart, M J ^a  

^a Translational Research Unit   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer; HER 2; Metastatic; Primary

Indexed keywords

ONCOPROTEIN; TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DIAGNOSTIC KIT; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; ONCOGENE NEU; PRIORITY JOURNAL; BREAST TUMOR; CANCER STAGING; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CULTURE TECHNIQUE; EPIDEMIOLOGY; FEMALE; MULTIPLE CANCER; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

BIOPSY, NEEDLE; BREAST NEOPLASMS; COHORT STUDIES; CONFIDENCE INTERVALS; CULTURE TECHNIQUES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; PROGNOSIS; RECEPTOR, ERBB-2; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0035990831     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf252     Document Type: Article

References (32)

1. Genetic alterations in breast cancer
2. Tumor cell societies
3. Growth dominance of the metastatic cancer cell: Cellular and molecular aspects
4. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer
5. HER-2/neu (c-erb-B2) gene and protein in breast cancer
6. Breast cancer in the 21st century: Neu opportunities and neu challenges
7. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
8. Correlation between long-term survival in breast cancer patients and amplification of two-putative oncogene co-amplification units: Hst-1/int-2 and c-erbB-2/ear-1
9. Predictive molecular markers: A new window of opportunity in the adjuvant therapy of breast cancer
10. Evaluation of Her-2/neu protein expression in breast cancer by immunohistochemistry: An interlaboratory study assessing the reproducibility of Her-2 testing
11. First-line, non-hormonal, treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody)
12. First-line single-agent Herceptin (H) therapy for women with HER2-overexpressing metastatic breast cancer (MBC)
13. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
14. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
15. Superior outcomes with Herceptin (trastuzumab) in fluorescence in situ hybridization (FISH)-selected patients
16. Evaluation of HER-2, p53, bcl-2, topoisomerase II-α, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes
17. Breast cancer heterogeneity: Evaluation of clonality in primary and metastatic lesions
18. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues
19. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma
20. Assessment of HER-2/neu overexpression in primary breast cancers and their metastatic lesions: An immunohistochemical study
21. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases
22. Amplification of HER-2/neu and topoisomerase II-α in primary and metastatic breast cancer
23. Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer
24. Increased erbB-2 gene copies and expression in multiple stages of breast cancer
25. Stability of HER-2/neu expression over time and at multiple metastatic sites
26. HER-2/neu/erbB-2 status by immunohistochemistry and FISH: Clonality and progression with recurrence and metastases
27. Clonal heterogeneity in breast cancer: Karyotypic comparisons of multiple intra- and extra-tumorous samples from 3 patients
28. Karyotypic comparisons of multiple tumours and macroscopically normal surrounding tissue samples from patients with breast cancer
29. Chromosome analysis of 97 primary breast carcinomas: Identification of eight karyotypic subgroups
30. Clonal chromosome abnormalities in human breast carcinoma II. Thirty-four cases with metastatic disease
31. Loss of oestrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy
32. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression